Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
Type 2 diabetes is believed to develop as a result of lowered insulin secretion and insulin resistance leading to hyperglycemia. Sulfonylureas stimulateinsulin secretion and thereby decrease blood glucose level which accounts for their wide application in the treatment of diabetes. However, manyagen...
Saved in:
| Main Authors: | Tatiana Ivanovna Romantsova, Nadezhda Viktorovna Maksimova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2010-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving the Glimepiride Efficacy in Type 2 Diabetes Treatment: A Review of the Potential Advantages and Disadvantages of Glimepiride as Hypoglycemic Oral Medication.
by: Gehad Abdelazeem Elshamy, et al.
Published: (2025-06-01) -
Myricetin Amplifies Glucose–Stimulated Insulin Secretion via the cAMP-PKA-Epac-2 Signaling Cascade
by: Akhtar Ali, et al.
Published: (2025-06-01) -
Side Effects Evaluation of the Use of Metformin and Glimepiride Combination In Type 2 Diabetes Mellitus Outpatients
by: Ni Nyoman Wahyu Udayani, et al.
Published: (2022-09-01) -
Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01) -
Glibenclamide - profile of efficacy and safety
by: Lyudmila Viktorovna Nedosugova
Published: (2011-09-01)